Answers are grounded in this paper and cite their sources.
In vitro and in silico study demonstrates potent VEGFR-2 inhibition by benzanilide derivatives in cancer cell lines, highlighting their potential as anticancer leads.
AIMS: This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis. MATERIALS AND METHODS: ) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound. RESULTS: = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles. CONCLUSIONS: represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.
No takes yet. Share an insight, caveat, or question.
Metwaly et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: